Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289067 | 0.93 | PDE3B (0.43) | PDE3BPDE3AP2RY12MAPTPTPN1 | |
| SCHEMBL6222298 | 0.90 | PDE3B (0.47) | PDE3BPDE3AP2RY12MAPTITGB1 | |
| SCHEMBL6281586 | 0.83 | MAPT (0.39) | MAPTPTPN1ITGB1ITGA5ITGB3 | |
| SCHEMBL6222810 | 0.83 | PDE3B (0.46) | PDE3BPDE3AP2RY12MAPTPTPN1 | |
| SCHEMBL6284775 | 0.75 | MAPK1 (0.46) | MAPTPTPN1ITGB1ITGA5CYSLTR2 | |
| SCHEMBL6289055 | 0.75 | ELANE (0.48) | PTPN1CYSLTR2CYSLTR1LTA4H | |
| SCHEMBL6286236 | 0.75 | MAPT (0.39) | MAPTPTPN1ITGB1ITGA5ITGB3 | |
| SCHEMBL6283666 | 0.75 | RAB9A (0.39) | PDE3BPDE3AP2RY12MAPTPTPN1 | |
| SCHEMBL6873358 | 0.74 | TDP1 (0.46) | ITGB1ITGA5ITGB3ITGA2BLTA4H | |
| SCHEMBL6730271 | 0.73 | ELANE (0.38) | PDE3BPDE3AP2RY12PTPN1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838453-B2 | Antagonist derivatives of the vitronectin receptor | AVENTIS PHARMA S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | ADGRF1, BDKRB1, ADGRE5 | PDE3B 980/4885PDE3A 816/4885P2RY12 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.